摘要
Abstract
OBJECTIVE: To investigate the effects of pravastatin on blood lipid and plasma inflammatory cytokines in patients with ischemic stroke. METHODS: 80 hospitalized patients with ischemic stroke were randomly divided into control group and pravastatin group. All patients were given nifedipine appropriately to control hypertension, mannitol to control intracranial pressure, cerebrolysin to nourish brain cells, aspilin anticoagulation and other symptomatic treatment. Pravastatin group were additionally given pravastatin 10 mg, qd for 4 weeks. The changes of TC, TG, LDL-C, HDL-C, hs-CRP, MMP-9 and neurologic impairment scores were compared between 2 groups, and clinical efficacy was also evaluated. RESULTS: After 4 weeks of treatment, TC, TG and LDL-C levels decreased significantly, compared with before treatment. HDL-C levels were significantly increased in pravastatin group (P<0.05). There were no statistically differences in control group before and after treatment (P>0.05); Plasma hs-CRP and MMP-9 levels decreased significantly, compared with before treatment (P<0.05 orP<0.01), and the decrease of them in pravastatin group were more significant than in control group (P<0.05); the neurological deficit scores of two groups were significantly decreased, compared with before treatment (P<0.01 or P<0.05), and the decrease of it in pravastatin group was more significant than control group (P<0.05). CONCLUSIONS: Treatment of ischemic stroke with pravastatin is effective, and its mechanism may be associated with decreasing blood lipid, reducing inflammation, improving atherosclerosis, then resulting in the improvement of ischemia and hypoxia and defects of neurological function.关键词
普伐他汀/缺血性脑卒中/血脂/超敏C反应蛋白/基质金属蛋白9Key words
Pravastatin/ Ischemic stroke/ Blood lipid/ hs-CRP/ MMP-9分类
医药卫生
